By Fineline Cube Simcere Pharmaceutical Group (HKG: 2096) announced that Culevibart Injection (trade name: Yingmule), a domestic Category 1 biological drug developed under its strategic cooperation with Reyoung (Shandong) Biopharmaceutical Co., Ltd., has been approved for marketing in China by the National Medical Products Administration (NMPA). The monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in newborns and infants entering their first RSV epidemic season, positioning Simcere as an early mover in one of pediatric prevention’s most sought-after categories.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Marketing approval |
| Product | Culevibart Injection (Yingmule), domestic Category 1 biological drug |
| Indication | Prevention of RSV lower respiratory tract infections in newborns/infants born at or after 35 weeks of gestational age entering or born during their first RSV epidemic season |
| Exclusions | Children with chronic lung disease, bronchopulmonary dysplasia (BPD) or clinically significant congenital respiratory abnormalities |
| Date | 03 Sept 2026 |
| Next Steps | Commercialization in China under Simcere’s exclusive Greater China rights |
Drug Profile & Mechanism of Action
- Molecule: Culevibart, a recombinant human IgG1κ monoclonal antibody
- Mechanism: Provides passive immunity by targeting epitope II of the RSV F protein, blocking viral entry
- Half-Life Extension: Fc segment engineering achieves an extended antibody half-life
- Dosing Regimen: A single intramuscular injection delivers continuous protection covering the entire RSV epidemic season
- Commercial Structure: On 20 August 2026, Simcere entered a strategic cooperation with Reyoung Bio, obtaining the exclusive commercialization rights of culevibart in Greater China
Clinical Evidence – Pivotal Phase III Study
| Endpoint | 150 Days Post-Dose | 240 Days Post-Dose |
|---|---|---|
| Efficacy against RSV LRTI requiring medical intervention (outpatient, emergency or hospitalization) | 85.32% | 82.04% |
| Efficacy against RSV infection-induced hospitalization | 83.27% | 78.44% |
The pivotal Phase III data underpinning the approval demonstrate strong and durable efficacy: at 150 days post-dose, culevibart showed 85.32% efficacy against RSV-caused lower respiratory tract infections requiring medical intervention and 83.27% efficacy against RSV infection-induced hospitalization. At 240 days post-dose, efficacy remained at 82.04% and 78.44% respectively — supporting the single-dose, full-season protection profile central to the product’s value proposition.
Market Impact & Outlook
- Large addressable population: Nearly all infants are exposed to RSV within their first years of life, and first-season protection via a single injection addresses a major unmet need in China’s pediatric preventive market
- Differentiated profile: Extended half-life enabling one-shot, full-season coverage offers a clear convenience and adherence advantage over shorter-lived passive immunization options
- Commercial control: Simcere’s exclusive Greater China rights (secured 20 August 2026) give the group full command of launch strategy, pricing and channel execution
- Partnership validation: The approval validates the Simcere–Reyoung Bio strategic cooperation model pairing discovery/development with scaled commercialization capability
- Category momentum: With RSV prevention becoming a global pediatric priority, Yingmule positions Simcere (HKG: 2096) among the first domestic players with an approved monoclonal antibody option in China
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding commercialization plans, market potential and product uptake are forward-looking and subject to risks and uncertainties, including pricing and reimbursement outcomes, competitive developments and real-world adoption. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech